Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Apr;63(4):431–437. doi: 10.1136/ard.2003.006346

Urinary tract infections and lupus erythematosus

C Hidalgo-Tenorio 1, J Jimenez-Alonso 1, Luna J de Dios 1, M Tallada 1, A Martinez-Brocal 1, S Mario 1
PMCID: PMC1754953  PMID: 15020339

Abstract

Background: Infections are one of the main causes of morbidity and mortality in patients with systemic lupus erythematosus.

Objective: To analyse urinary tract infection (UTI) risk factors in lupus patients; the influence of these factors on disease activity, organ damage, and disease development; the type and prevalence of UTI; and the micro-organisms involved.

Method: 86 control subjects and 81 lupus patients were studied prospectively over a 12 month period and examined on five occasions. Epidemiological data and information on urinary symptoms, disease activity (SLEDAI), and organ damage (SLICC/ACR) data were collected. Autoantibodies, complement levels, urine culture, and antibiogram were determined; urological studies were also carried out. SPPS 10.0 and STATA 6.0. were used for statistical analysis.

Results: The prevalence of UTI in lupus patients was 36%. Lupus influences the onset of UTI (p = 0.001), regardless of other variables. UTI risk factors in lupus patients were age (p = 0.002), previous cases of UTI (p = 0.0001), antinuclear antibodies (ANA) >1/80 IU/ml (p = 0.022), thrombocytopenia (p = 0.02), and admission to hospital due to UTI (p = 0.002). Leucopenia (p = 0.09) and the weekly administration of methotrexate (p = 0.06) had a bearing on the onset of UTI; disease development (p = 0.99), lupus activity (p = 0.32), and organ damage (p = 0.36) do not. The uropathogen most frequently isolated was E coli (60%).

Conclusions: Lupus patients are likely to have UTI, usually manifesting in the lower tract. They are community acquired, basically caused by E coli, and favoured by age, previous UTI, admissions to hospital due to UTI, thrombopenia, ANA, leucopenia, and methotrexate treatments.

Full Text

The Full Text of this article is available as a PDF (250.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abu-Shakra M., Mader R., Langevitz P., Friger M., Codish S., Neumann L., Buskila D. Quality of life in systemic lupus erythematosus: a controlled study. J Rheumatol. 1999 Feb;26(2):306–309. [PubMed] [Google Scholar]
  2. Björnsdóttir L. T., Geirsson R. T., Jónsson P. V. Urinary incontinence and urinary tract infections in octogenarian women. Acta Obstet Gynecol Scand. 1998 Jan;77(1):105–109. doi: 10.1034/j.1600-0412.1998.770122.x. [DOI] [PubMed] [Google Scholar]
  3. Bloom D. A., Foster W. D., McLeod D. G., Mittemeyer B. T., Stutzman R. E. Cost-effective uroflowmetry in men. J Urol. 1985 Mar;133(3):421–424. doi: 10.1016/s0022-5347(17)49003-3. [DOI] [PubMed] [Google Scholar]
  4. Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chang C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630–640. doi: 10.1002/art.1780350606. [DOI] [PubMed] [Google Scholar]
  5. Cervera R., Khamashta M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Aydintug A. O., Jedryka-Góral A., de Ramón E., Fernández-Nebro A. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999 May;78(3):167–175. doi: 10.1097/00005792-199905000-00003. [DOI] [PubMed] [Google Scholar]
  6. Chancellor M. B., Rivas D. A., Mulholland S. G., Drake W. M., Jr The invention of the modern uroflowmeter by Willard M. Drake, Jr at Jefferson Medical College. Urology. 1998 Apr;51(4):671–674. doi: 10.1016/s0090-4295(97)00203-3. [DOI] [PubMed] [Google Scholar]
  7. Cunha B. A. Infections in nonleukopenic compromised hosts (diabetes mellitus, SLE, steroids, and asplenia) in critical care. Crit Care Clin. 1998 Apr;14(2):263–282. doi: 10.1016/s0749-0704(05)70395-x. [DOI] [PubMed] [Google Scholar]
  8. Duffy K. N., Duffy C. M., Gladman D. D. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol. 1991 Aug;18(8):1180–1184. [PubMed] [Google Scholar]
  9. Dupont M. C., Albo M. E., Raz S. Diagnosis of stress urinary incontinence. An overview. Urol Clin North Am. 1996 Aug;23(3):407–415. doi: 10.1016/s0094-0143(05)70321-9. [DOI] [PubMed] [Google Scholar]
  10. Eckford S. D., Keane D. P., Lamond E., Jackson S. R., Abrams P. Hydration monitoring in the prevention of recurrent idiopathic urinary tract infections in pre-menopausal women. Br J Urol. 1995 Jul;76(1):90–93. doi: 10.1111/j.1464-410x.1995.tb07839.x. [DOI] [PubMed] [Google Scholar]
  11. Formiga Pérez F., Moga Sampere I., Canet González R., Pac Ferraz M., Mitjavila Villero F., Fernández Nogués F. Infección y lupus eritematoso sistémico: análisis de una serie de 145 pacientes. Rev Clin Esp. 1993 Jul;193(3):105–109. [PubMed] [Google Scholar]
  12. Garau J., Xercavins M., Rodríguez-Carballeira M., Gómez-Vera J. R., Coll I., Vidal D., Llovet T., Ruíz-Bremón A. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999 Nov;43(11):2736–2741. doi: 10.1128/aac.43.11.2736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gladman D. D., Hussain F., Ibañez D., Urowitz M. B. The nature and outcome of infection in systemic lupus erythematosus. Lupus. 2002;11(4):234–239. doi: 10.1191/0961203302lu170oa. [DOI] [PubMed] [Google Scholar]
  14. Gladman D. D., Urowitz M. B., Goldsmith C. H., Fortin P., Ginzler E., Gordon C., Hanly J. G., Isenberg D. A., Kalunian K., Nived O. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997 May;40(5):809–813. doi: 10.1002/art.1780400506. [DOI] [PubMed] [Google Scholar]
  15. Gómez J., Palazón D., Ortega G., Lucas E., Bru M., Campillo M., Torralba M., Canteras M., Sánchez Gascón F. Infecciones y lupus eritematoso sistémico. Análisis de factores de riesgo y pronóstico. Estudio prospectivo (1979-1988). Rev Clin Esp. 1991 Feb;188(2):72–75. [PubMed] [Google Scholar]
  16. Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725–1725. doi: 10.1002/art.1780400928. [DOI] [PubMed] [Google Scholar]
  17. Hooton T. M., Roberts P. L., Stamm W. E. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis. 1994 Aug;19(2):274–278. doi: 10.1093/clinids/19.2.274. [DOI] [PubMed] [Google Scholar]
  18. Hooton T. M., Scholes D., Hughes J. P., Winter C., Roberts P. L., Stapleton A. E., Stergachis A., Stamm W. E. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med. 1996 Aug 15;335(7):468–474. doi: 10.1056/NEJM199608153350703. [DOI] [PubMed] [Google Scholar]
  19. Hooton T. M., Scholes D., Stapleton A. E., Roberts P. L., Winter C., Gupta K., Samadpour M., Stamm W. E. A prospective study of asymptomatic bacteriuria in sexually active young women. N Engl J Med. 2000 Oct 5;343(14):992–997. doi: 10.1056/NEJM200010053431402. [DOI] [PubMed] [Google Scholar]
  20. Hooton TM. Pathogenesis of urinary tract infections: an update. J Antimicrob Chemother. 2000 Aug;46 (Suppl A):1–7. [PubMed] [Google Scholar]
  21. Jacobsen S., Petersen J., Ullman S., Junker P., Voss A., Rasmussen J. M., Tarp U., Poulsen L. H., van Overeem Hansen G., Skaarup B. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol. 1998;17(6):478–484. doi: 10.1007/BF01451283. [DOI] [PubMed] [Google Scholar]
  22. Janwityanuchit S., Totemchokchyakarn K., Krachangwongchai K., Vatanasuk M. Infection in systemic lupus erythematosus. J Med Assoc Thai. 1993 Oct;76(10):542–548. [PubMed] [Google Scholar]
  23. Juega J., Pedreira J. D., Adega M., Valdés F., Echaniz A. Infección en el lupus eritematoso sistémico. Rev Clin Esp. 1989 Mar;184(5):245–246. [PubMed] [Google Scholar]
  24. Kahlmeter G. The ECO*SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother. 2000 Aug;46 (Suppl A):15–22. [PubMed] [Google Scholar]
  25. Klippel J. H. Systemic lupus erythematosus. Treatment-related complications superimposed on chronic disease. JAMA. 1990 Apr 4;263(13):1812–1815. doi: 10.1001/jama.263.13.1812. [DOI] [PubMed] [Google Scholar]
  26. Koseda-Dragan M., Hebanowski M., Galiński J., Krzywińska E., Bakowska A. Bakteriomocz bezobjawowy u kobiet z rozpoznaniem tocznia rumieniowatego układowego (T.R.U.). Pol Arch Med Wewn. 1998 Oct;100(4):321–330. [PubMed] [Google Scholar]
  27. Kunin C. M. Urinary tract infections in females. Clin Infect Dis. 1994 Jan;18(1):1–12. doi: 10.1093/clinids/18.1.1. [DOI] [PubMed] [Google Scholar]
  28. Le Moing V., Leport C. Infections et lupus. Rev Prat. 1998 Mar 15;48(6):637–642. [PubMed] [Google Scholar]
  29. Lim E., Koh W. H., Loh S. F., Lam M. S., Howe H. S. Non-thyphoidal salmonellosis in patients with systemic lupus erythematosus. A study of fifty patients and a review of the literature. Lupus. 2001;10(2):87–92. doi: 10.1191/096120301675973164. [DOI] [PubMed] [Google Scholar]
  30. Locke G. R., 3rd, Pemberton J. H., Phillips S. F. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology. 2000 Dec;119(6):1761–1766. doi: 10.1053/gast.2000.20390. [DOI] [PubMed] [Google Scholar]
  31. Noël V., Lortholary O., Casassus P., Cohen P., Généreau T., André M. H., Mouthon L., Guillevin L. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001 Dec;60(12):1141–1144. doi: 10.1136/ard.60.12.1141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Paton N. I., Cheong I. K., Kong N. C., Segasothy M. Risk factors for infection in Malaysian patients with systemic lupus erythematosus. QJM. 1996 Jul;89(7):531–538. doi: 10.1093/qjmed/89.7.531. [DOI] [PubMed] [Google Scholar]
  33. Paton N. I. Infections in systemic lupus erythematosus patients. Ann Acad Med Singapore. 1997 Sep;26(5):694–700. [PubMed] [Google Scholar]
  34. Petri M., Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. J Rheumatol. 1992 Oct;19(10):1559–1565. [PubMed] [Google Scholar]
  35. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am. 1998 May;24(2):423–456. doi: 10.1016/s0889-857x(05)70016-8. [DOI] [PubMed] [Google Scholar]
  36. Pryor B. D., Bologna S. G., Kahl L. E. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996 Sep;39(9):1475–1482. doi: 10.1002/art.1780390906. [DOI] [PubMed] [Google Scholar]
  37. Rojas-Serrano J., Cardiel M. H. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus. 2000;9(8):601–606. doi: 10.1191/096120300678828785. [DOI] [PubMed] [Google Scholar]
  38. Staples P. J., Gerding D. N., Decker J. L., Gordon R. S., Jr Incidence of infection in systemic lupus erythematosus. Arthritis Rheum. 1974 Jan-Feb;17(1):1–10. doi: 10.1002/art.1780170102. [DOI] [PubMed] [Google Scholar]
  39. Stratton M. A. Drug-induced systemic lupus erythematosus. Clin Pharm. 1985 Nov-Dec;4(6):657–663. [PubMed] [Google Scholar]
  40. Tishler M., Caspi D., Almog Y., Segal R., Yaron M. Increased incidence of urinary tract infection in patients with rheumatoid arthritis and secondary Sjögren's syndrome. Ann Rheum Dis. 1992 May;51(5):604–606. doi: 10.1136/ard.51.5.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Urowitz M. B., Gladman D. D. Evolving spectrum of mortality and morbidity in SLE. Lupus. 1999;8(4):253–255. doi: 10.1191/096120399678847821. [DOI] [PubMed] [Google Scholar]
  42. Uthman I., Soucy J. P., Nicolet V., Senécal J. L. Autosplenectomy in systemic lupus erythematosus. J Rheumatol. 1996 Oct;23(10):1806–1810. [PubMed] [Google Scholar]
  43. Varela Aguilar J. M., Sánchez Román J., Bravo-Ferrer J. Infecciones graves en el lupus eritematoso sistémico. Rev Clin Esp. 1990 Feb;186(2):97–98. [PubMed] [Google Scholar]
  44. Wagenlehner F. M., Naber K. G. Uncomplicated urinary tract infections in women. Curr Opin Urol. 2001 Jan;11(1):49–53. doi: 10.1097/00042307-200101000-00007. [DOI] [PubMed] [Google Scholar]
  45. Ward M. M., Pyun E., Studenski S. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum. 1995 Oct;38(10):1492–1499. doi: 10.1002/art.1780381016. [DOI] [PubMed] [Google Scholar]
  46. Warren J. W., Abrutyn E., Hebel J. R., Johnson J. R., Schaeffer A. J., Stamm W. E. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999 Oct;29(4):745–758. doi: 10.1086/520427. [DOI] [PubMed] [Google Scholar]
  47. de Luis A., Pigrau C., Pahissa A., Fernández F., Martínez-Vázquez J. M. Infecciones en 96 casos de lupus eritematoso sistémico. Med Clin (Barc) 1990 Apr 28;94(16):607–610. [PubMed] [Google Scholar]
  48. ter Borg E. J., Horst G., Hummel E., Limburg P. C., Kallenberg C. G. Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation. Clin Immunol Immunopathol. 1991 Apr;59(1):117–128. doi: 10.1016/0090-1229(91)90086-p. [DOI] [PubMed] [Google Scholar]
  49. van Haarst E. P., van Andel G., Heldeweg E. A., Schlatmann T. J., van der Horst H. J. Evaluation of the diagnostic workup in young women referred for recurrent lower urinary tract infections. Urology. 2001 Jun;57(6):1068–1072. doi: 10.1016/s0090-4295(01)00971-2. [DOI] [PubMed] [Google Scholar]
  50. van der Veen M. J., van der Heide A., Kruize A. A., Bijlsma J. W. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994 Apr;53(4):224–228. doi: 10.1136/ard.53.4.224. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES